You are here

Our science / Clinical Trials / Find a Trial / NCT00888576

Registry of Etanercept Use in Patients With Rheumatoid Arthritis in Clinical Practice in Taiwan

Back to Search Print Save as PDF Bookmark Trial

NCT00888576

Last updated on April 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Changhua City, Changhua County, 500 Taiwan
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Main Inclusion Criteria: 1) Male or female patients aged > 20 years; 2) Patients who have
already been selected and approved under the Taiwan National Health Insurance Program to
receive 24 weeks of etanercept for rheumatoid arthritis. Main

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Exclusion Criteria: None

NCT00888576
Pfizer
Completed
Registry of Etanercept Use in Patients With Rheumatoid Arthritis in Clinical Practice in Taiwan

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Rheumatoid Arthritis
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
NCT02092467
All Genders
50+
Years
Multiple Sites
Psoriatic Arthritis
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
NCT01976364
All Genders
18+
Years
Multiple Sites
Arthritis Juvenile Idiopathic
A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA
NCT03000439
All Genders
2+
Years
Multiple Sites
Rheumatoid Arthritis
Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions
NCT03073109
All Genders
18+
Years
Multiple Sites
Registry of Etanercept Use in Patients With Rheumatoid Arthritis in Clinical Practice in Taiwan
A Registry Study to Describe the Implications of Therapeutic Management of Etanercept in Patients With Rheumatoid Arthritis
The purpose of this study is to develop a registry with safety and efficacy data on the use of etanercept in clinical practice in Taiwan.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
clinic
Rheumatoid Arthritis
Not Provided
1
Non-intervention
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
441
December 2011
December 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Main Inclusion Criteria: 1) Male or female patients aged > 20 years; 2) Patients who have already been selected and approved under the Taiwan National Health Insurance Program to receive 24 weeks of etanercept for rheumatoid arthritis. Main

Exclusion Criteria:

Exclusion Criteria: None
Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
 
NCT00888576
0881A1-4445
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
February 2012

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now